Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Belén Garijo López

CEOBelén Garijo López

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

102.42B

Market cap102.42B

Price-Earnings ratio

17.18

Price-Earnings ratio17.18

Dividend yield

4.27%

Dividend yield4.27%

Average volume

4.97M

Average volume4.97M

High today

$42.14

High today$42.14

Low today

$41.35

Low today$41.35

Open price

$41.50

Open price$41.50

Volume

4.52M

Volume4.52M

52 Week high

$52.68

52 Week high$52.68

52 Week low

$40.89

52 Week low$40.89

SNY News

Investor's Business Daily 16h

Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?

Technology Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi? Licensing Kymera Therapeutics (KYMR) shares catapulted Thursday after the company...

TipRanks 2d

Sanofi Secures Multiple June Approvals and New R&D Chief to Bolster Oncology and Neurology Push

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 3d

Sanofi’s RSV Study in Queensland: What Real-World Uptake Could Mean for Investors

Sanofi SA (SNY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more co...

Analyst ratings

57%

of 7 ratings

Buy

42.9%

Hold

57.1%

Sell

More SNY News

The Wall Street Journal 3d

Sanofi Multiple Sclerosis Drug Gets EU Approval

The U.S. Food and Drug Administration declined Sanofi’s application for multiple sclerosis drug Cenrifki in December last year. Guillaume Souvant / Agence Franc...

TipRanks 3d

MacroGenics to receive $24.5M milestone payment from Sanofi

MacroGenics (MGNX) announced that it will receive a $24.5M regulatory milestone payment from Sanofi (SNY) following the U.S. Food and Drug Administration’s acce...

TipRanks 4d

Sanofi Wins FDA Accelerated Approval for Tzield in Newly Diagnosed Stage 3 Type 1 Diabetes Children

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 4d

Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi (SNY) announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President, Global Head of Research & Development Pharma, effective Se...

TipRanks 4d

Sanofi investors likely to view new R&D head as a positive, says BofA

After Sanofi (SNY) announced a new head of R&D with Paulo Fontoura replacing Houman Ashrafian, BofA analyst Sachin Jain says investors are likely to view Fontou...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.